A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...
James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...
By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Managed Care have been published. According to news reporting out of San Francisco, California, by NewsRx ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback